Product Information

IBUPROFEN-FAMOTIDIN 800-26.6 MG is a generic product labeled by Ascend Laboratories, LLC, priced at $0.7938 per EA under NDC 67877062690. Its NADAC has been published 248 times since Feb 23, 2022.

FDA first approved this application on Aug 3, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

IBUPROFEN-FAMOTIDIN 800-26.6 MG

Ibuprofen and famotidine
$0.7938per EA

Strength

26.6; 800 mg/1; mg/1

NDC

67877062690

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

FAMOTIDINE; IBUPROFEN

Approval Type

Generic (ANDA)

FDA Application

ANDA211890

FDA Approved

8/3/2021

TE Code

AB

On Market Since

8/4/2021

Pharmacological Classes

Anti-Inflammatory Agents
Non-Steroidal
Cyclooxygenase Inhibitors
Histamine H2 Receptor Antagonists
Histamine-2 Receptor Antagonist
Nonsteroidal Anti-inflammatory Drug

Price Statistics

The NADAC for IBUPROFEN-FAMOTIDIN 800-26.6 MG has been published 248 times since Feb 23, 2022, and over the history we have for it it has declined 79.1%. The table below summarizes its recorded NADAC range and movement.

Current price$0.7938 per EA
All-time high$4.1664 (Nov 16, 2022)
All-time low$0.6418 (Feb 18, 2026)
52-week high$0.9449
52-week low$0.6418
Median price$1.5439
Average price$1.9814
Largest weekly change+71.1% (Aug 23, 2023)
Weeks tracked248
Tracking sinceFeb 23, 2022

Price History

1W

+7.8%

1M

+11.2%

3M

+3.2%

6M

-15.7%

1Y

+11.5%

3Y

-74.4%

5Y

N/A

All

-79.1%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of IBUPROFEN-FAMOTIDIN 800-26.6 MG?

The current National Average Drug Acquisition Cost (NADAC) for IBUPROFEN-FAMOTIDIN 800-26.6 MG, manufactured by Ascend Laboratories, LLC, is $0.7938 per EA (NDC 67877062690), effective Nov 18, 2026.

How has the price of IBUPROFEN-FAMOTIDIN 800-26.6 MG changed over time?

Over the history we have for it, the NADAC for IBUPROFEN-FAMOTIDIN 800-26.6 MG has declined 79.1%. It has been tracked across 248 weekly CMS publications since Feb 23, 2022.

What are the highest and lowest recorded NADAC prices for IBUPROFEN-FAMOTIDIN 800-26.6 MG?

Since Feb 23, 2022, the NADAC for IBUPROFEN-FAMOTIDIN 800-26.6 MG has ranged from a low of $0.6418 (Feb 18, 2026) to a high of $4.1664 (Nov 16, 2022), with a median of $1.5439 per EA.

Are there cheaper alternatives to IBUPROFEN-FAMOTIDIN 800-26.6 MG?

2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as IBUPROFEN-FAMOTIDIN 800-26.6 MG in a comparable dosage form, but none are currently priced below it.

Who manufactures IBUPROFEN-FAMOTIDIN 800-26.6 MG?

IBUPROFEN-FAMOTIDIN 800-26.6 MG (NDC 67877062690) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.